Glenn D Wong, DO
Hematology/Oncology · Santa Cruz
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Dominican Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Wong’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$4,290,465
Medicare paid this office $4,290,465 for 1,010 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 16 | $527,152 | None |
| Injection, nivolumab, 1 mg | 12 | $439,684 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 20 | $201,564 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $146,086 | None |
| Injection, tocilizumab, 1 mg | 18 | $128,988 | None |
See all 54 services
| Injection, pembrolizumab, 1 mg | 16 | $527,152 | None |
| Injection, nivolumab, 1 mg | 12 | $439,684 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 20 | $201,564 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $146,086 | None |
| Injection, tocilizumab, 1 mg | 18 | $128,988 | None |
| Long return visit (40+ min) | 220 | $126,992 | $148 |
| Injection, denosumab, 1 mg | 20 | $116,649 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $91,163 | None |
| Return visit (30+ min) | 384 | $74,912 | $99 |
| Injection, golimumab, 1 mg, for intravenous use | 25 | $74,005 | None |
| Administration of chemotherapy into vein, 1 hour or less | 141 | $48,505 | $119 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 17 | $39,975 | $107 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 257 | $34,219 | $56 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 18 | $33,121 | $16 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 370 | $14,320 | $13 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $13,761 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $12,364 | None |
| Bcg live intravesical instillation, 1 mg | 41 | $10,082 | None |
| New patient visit (60+ min) | 54 | $9,653 | $179 |
| Administration of additional new drug or substance into vein, 1 hour or less | 48 | $7,568 | $58 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $7,378 | $66 |
| Instillation of anti-cancer drug into bladder | 43 | $7,094 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 55 | $6,341 | $18 |
| Injection, iron dextran, 50 mg | 18 | $5,897 | None |
| Injection of additional new drug or substance into vein | 95 | $5,483 | $14 |
| Administration of chemotherapy into vein, each additional hour | 46 | $4,640 | $25 |
| Collection of blood sample from implanted device | 54 | $4,253 | $25 |
| Drawing of blood for a medical problem | 20 | $4,122 | $86 |
| Injection of drug or substance under skin or into muscle | 87 | $3,479 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $3,296 | $26 |
| Administration of additional new drug or substance into vein using push technique | 23 | $2,951 | $50 |
| Injection of drug or substance into vein | 56 | $2,686 | $32 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $2,568 | $0 |
| Injection, zoledronic acid, 1 mg | 103 | $2,565 | None |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 68 | $2,382 | $27 |
| New patient visit (45+ min) | 15 | $1,955 | $130 |
| Infusion into a vein for hydration, 31-60 minutes | 26 | $1,952 | $28 |
| Injection, leucovorin calcium, per 50 mg | 12 | $1,804 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $1,581 | $32 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 65 | $1,434 | $20 |
| Injection, fosaprepitant, 1 mg | 27 | $992 | None |
| Injection, fluorouracil, 500 mg | 13 | $834 | None |
| Injection, paclitaxel, 1 mg | 14 | $778 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 24 | $685 | $18 |
| Injection, carboplatin, 50 mg | 15 | $665 | None |
| Irrigation of implanted venous access drug delivery device | 15 | $431 | $22 |
| Infusion into a vein for hydration, each additional hour | 12 | $320 | $11 |
| Injection, methylprednisolone sodium succinate, 5 mg | 13 | $252 | None |
| Infusion, normal saline solution , 1000 cc | 28 | $160 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 52 | $122 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 51 | $110 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 54 | $81 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 19 | $48 | None |
| Unclassified drugs | 17 | $26 | None |
Who their Medicare patients are
1,010 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 12% · Women 58% · Also on Medicaid 13% · Health risk score 1.60. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 63% · Cancer 40% · Coronary heart disease 20% · Chronic kidney disease 20% · Depression 20% · Diabetes 18% · Atrial fibrillation 17% · COPD 14% · Heart failure 13% · Dementia 5% · Stroke 4%.
The office billed $14,716,039, Medicare allowed $5,405,900 and paid $4,290,465; for 244,090 services of 153 kinds; $3,895,517 of it was for drugs given in the office and $394,948 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,010 | 244,090 | 75 | 1.60 | $14,716,039 | $4,290,465 |
| 2023 | 898 | 206,236 | 75 | 1.53 | $13,816,592 | $4,159,164 |
| 2022 | 817 | 167,862 | 74 | 1.48 | $10,970,678 | $3,453,055 |
| 2021 | 837 | 205,429 | 75 | 1.47 | $11,378,195 | $3,786,729 |
| 2020 | 870 | 244,728 | 74 | 1.60 | $13,324,302 | $4,457,400 |
| 2019 | 910 | 218,071 | 74 | 1.54 | $10,159,042 | $3,268,233 |
| 2018 | 889 | 209,576 | 74 | 1.58 | $9,611,653 | $2,947,121 |
| 2017 | 813 | 208,928 | 74 | 1.57 | $9,799,233 | $2,994,722 |
| 2016 | 681 | 157,129 | 74 | 1.55 | $8,748,606 | $2,494,453 |
| 2015 | 647 | 114,903 | 73 | 1.49 | $7,257,092 | $2,162,047 |
| 2014 | 630 | 79,039 | 73 | 1.39 | $5,653,023 | $1,440,945 |
| 2013 | 554 | 57,427 | 73 | 1.44 | $5,814,744 | $1,455,099 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 51 services
| Injection, nivolumab, 1 mg | 14 | $482,655 | None |
| Injection, pembrolizumab, 1 mg | 22 | $362,621 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $246,890 | None |
| Injection, denosumab, 1 mg | 21 | $123,778 | None |
| Long return visit (40+ min) | 176 | $98,535 | $151 |
| Return visit (30+ min) | 385 | $79,280 | $100 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15 | $71,387 | None |
| Injection, golimumab, 1 mg, for intravenous use | 17 | $59,248 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 17 | $53,833 | $21 |
| Administration of chemotherapy into vein, 1 hour or less | 153 | $47,800 | $125 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 12 | $31,932 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 197 | $27,947 | $60 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 11 | $14,410 | None |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 14 | $13,508 | $6 |
| New patient visit (60+ min) | 67 | $12,411 | $185 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $12,338 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $11,831 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $8,551 | $70 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $7,175 | $61 |
| Bcg live intravesical instillation, 1 mg | 31 | $5,573 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 39 | $5,220 | $19 |
| Cyclophosphamide, 100 mg | 12 | $5,220 | None |
| Instillation of anti-cancer drug into bladder | 33 | $4,181 | $73 |
| Injection of drug or substance under skin or into muscle | 89 | $3,956 | $13 |
| Injection of additional new drug or substance into vein | 76 | $3,887 | $14 |
| Drawing of blood for a medical problem | 16 | $3,586 | $87 |
| Injection, zoledronic acid, 1 mg | 86 | $3,399 | None |
| Administration of chemotherapy into vein, each additional hour | 42 | $3,395 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 51 | $3,257 | $27 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15 | $3,128 | $0 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 11 | $2,687 | $0 |
| New patient visit (45+ min) | 20 | $2,624 | $131 |
| Collection of blood sample from implanted device | 45 | $2,559 | $25 |
| Administration of additional new drug or substance into vein using push technique | 20 | $2,363 | $53 |
| Injection of drug or substance into vein | 35 | $2,186 | $34 |
| Infusion into a vein for hydration, 31-60 minutes | 24 | $1,758 | $31 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $1,658 | $32 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 60 | $1,534 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 29 | $919 | $18 |
| Injection, fosaprepitant, 1 mg | 28 | $801 | None |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $745 | $28 |
| Infusion into a vein for hydration, each additional hour | 28 | $427 | $12 |
| Injection, paclitaxel, 1 mg | 12 | $320 | None |
| Injection, carboplatin, 50 mg | 11 | $206 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 15 | $197 | None |
| Infusion, normal saline solution , 1000 cc | 31 | $145 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 53 | $132 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 57 | $109 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $73 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 17 | $32 | None |
| Unclassified drugs | 12 | $10 | None |
2022: 38 services
| Long return visit (40+ min) | 121 | $94,197 | $152 |
| Return visit (30+ min) | 401 | $88,424 | $102 |
| Injection, denosumab, 1 mg | 16 | $71,326 | None |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 21 | $52,778 | $6 |
| Injection, golimumab, 1 mg, for intravenous use | 15 | $46,839 | None |
| Administration of chemotherapy into vein, 1 hour or less | 115 | $46,500 | $132 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 161 | $27,380 | $64 |
| New patient visit (60+ min) | 48 | $9,200 | $192 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $8,731 | $73 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 20 | $6,303 | $0 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $5,851 | $64 |
| Bcg live intravesical instillation, 1 mg | 24 | $5,692 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 40 | $4,838 | $20 |
| Instillation of anti-cancer drug into bladder | 29 | $4,782 | $81 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 44 | $4,512 | $29 |
| Collection of blood sample from implanted device | 54 | $4,495 | $25 |
| Drawing of blood for a medical problem | 19 | $4,208 | $91 |
| Injection of additional new drug or substance into vein | 63 | $4,138 | $15 |
| Injection of drug or substance under skin or into muscle | 78 | $4,006 | $13 |
| Injection, iron dextran, 50 mg | 14 | $3,806 | None |
| Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | 21 | $3,726 | $177 |
| New patient visit (45+ min) | 26 | $3,610 | $139 |
| Administration of chemotherapy into vein, each additional hour | 41 | $2,864 | $28 |
| Administration of additional new drug or substance into vein using push technique | 11 | $2,433 | $55 |
| Injection, zoledronic acid, 1 mg | 60 | $2,192 | None |
| Short return visit (20+ min) | 27 | $1,412 | $50 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,307 | $31 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 36 | $1,036 | $22 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $833 | $28 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $820 | $32 |
| Injection, fosaprepitant, 1 mg | 14 | $540 | None |
| Injection of drug or substance into vein | 11 | $518 | $37 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 16 | $158 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $109 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 43 | $100 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $98 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 35 | $77 | None |
| Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | 18 | $0 | $0 |
2021: 49 services
| Injection, pembrolizumab, 1 mg | 24 | $409,797 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 14 | $120,674 | $51 |
| Injection, denosumab, 1 mg | 24 | $98,931 | None |
| Long return visit (40+ min) | 147 | $96,814 | $153 |
| Return visit (30+ min) | 356 | $86,357 | $100 |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $67,122 | None |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 12 | $62,274 | $192 |
| Administration of chemotherapy into vein, 1 hour or less | 133 | $59,664 | $138 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 15 | $50,355 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 167 | $31,398 | $68 |
| Bcg live intravesical instillation, 1 mg | 45 | $20,283 | None |
| Instillation of anti-cancer drug into bladder | 51 | $15,163 | $80 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $10,631 | $77 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $10,214 | $67 |
| Short return visit (20+ min) | 81 | $8,884 | $69 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 13 | $7,681 | $154 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 23 | $7,623 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 64 | $6,836 | $30 |
| Injection of additional new drug or substance into vein | 84 | $6,059 | $16 |
| Administration of chemotherapy into vein, each additional hour | 51 | $5,294 | $29 |
| Collection of blood sample from implanted device | 55 | $5,273 | $25 |
| New patient visit (60+ min) | 28 | $5,269 | $188 |
| Injection of drug or substance under skin or into muscle | 82 | $4,468 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $3,807 | $20 |
| Administration of additional new drug or substance into vein using push technique | 15 | $3,706 | $58 |
| Drawing of blood for a medical problem | 17 | $3,574 | $92 |
| Injection, iron dextran, 50 mg | 15 | $3,467 | None |
| Injection, zoledronic acid, 1 mg | 75 | $3,341 | None |
| New patient visit (45+ min) | 22 | $3,215 | $146 |
| Infusion into a vein for hydration, 31-60 minutes | 21 | $1,873 | $33 |
| Injection, leucovorin calcium, per 50 mg | 13 | $1,789 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 59 | $1,550 | $21 |
| Injection, fosaprepitant, 1 mg | 15 | $1,548 | None |
| Injection, paclitaxel, 1 mg | 16 | $1,209 | None |
| Injection of drug or substance into vein | 25 | $1,169 | $37 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $1,148 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,010 | $31 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 18 | $806 | $29 |
| Injection, oxaliplatin, 0.5 mg | 11 | $752 | None |
| Injection, fluorouracil, 500 mg | 13 | $714 | None |
| Irrigation of implanted venous access drug delivery device | 16 | $583 | $25 |
| Injection, carboplatin, 50 mg | 14 | $578 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $546 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 62 | $227 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 23 | $182 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 54 | $170 | None |
| Infusion, normal saline solution , 1000 cc | 19 | $122 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 50 | $101 | None |
| Insertion of needle into vein for collection of blood sample | 17 | $57 | $3 |
2020: 57 services
| Injection, pembrolizumab, 1 mg | 32 | $577,761 | None |
| Injection, nivolumab, 1 mg | 12 | $224,117 | None |
| Injection, rituximab, 10 mg | 17 | $200,425 | None |
| Injection, pegfilgrastim, 6 mg | 18 | $151,613 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $147,305 | None |
| Return visit (30+ min) | 429 | $123,846 | $88 |
| Injection, denosumab, 1 mg | 19 | $115,196 | None |
| Injection, golimumab, 1 mg, for intravenous use | 14 | $110,349 | None |
| Administration of chemotherapy into vein, 1 hour or less | 179 | $80,591 | $130 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 19 | $51,790 | $7 |
| Injection, infliximab, excludes biosimilar, 10 mg | 13 | $44,262 | None |
| Long return visit (40+ min) | 118 | $30,278 | $124 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 170 | $29,571 | $65 |
| Bcg live intravesical instillation, 1 mg | 33 | $15,409 | None |
| Instillation of anti-cancer drug into bladder | 37 | $10,716 | $75 |
| New patient visit (60+ min) | 57 | $10,038 | $176 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $9,629 | $74 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 90 | $9,268 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 49 | $9,059 | $63 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 18 | $8,265 | $0 |
| Injection, fosaprepitant, 1 mg | 20 | $7,957 | None |
| Administration of chemotherapy into vein, each additional hour | 64 | $7,650 | $28 |
| Injection of additional new drug or substance into vein | 108 | $6,542 | $15 |
| Drawing of blood for a medical problem | 32 | $6,443 | $87 |
| Injection, iron dextran, 50 mg | 26 | $5,683 | None |
| Injection of drug or substance under skin or into muscle | 80 | $5,534 | $13 |
| Collection of blood sample from implanted device | 81 | $5,526 | $23 |
| Administration of additional new drug or substance into vein using push technique | 27 | $5,198 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $4,902 | $20 |
| Injection, zoledronic acid, 1 mg | 72 | $2,946 | None |
| Short return visit (20+ min) | 34 | $2,789 | $57 |
| Extended patient service without direct patient contact, first hour | 26 | $2,721 | $97 |
| New patient visit (45+ min) | 17 | $2,257 | $133 |
| Infusion into a vein for hydration, 31-60 minutes | 26 | $2,143 | $32 |
| Administration of chemotherapy into vein using push technique | 12 | $2,122 | $101 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $1,880 | $94 |
| Injection, leucovorin calcium, per 50 mg | 15 | $1,769 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 64 | $1,540 | $19 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $1,419 | None |
| Injection, oxaliplatin, 0.5 mg | 15 | $1,392 | None |
| Injection, paclitaxel, 1 mg | 24 | $1,370 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,297 | $29 |
| Irrigation of implanted venous access drug delivery device | 22 | $985 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 15 | $842 | $19 |
| Injection, carboplatin, 50 mg | 18 | $755 | None |
| Injection of drug or substance into vein | 21 | $720 | $33 |
| Injection, fluorouracil, 500 mg | 15 | $631 | None |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 19 | $254 | $13 |
| Injection, ondansetron hydrochloride, per 1 mg | 72 | $248 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 81 | $246 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 15 | $177 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $149 | $12 |
| Infusion, normal saline solution , 1000 cc | 26 | $141 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 58 | $109 | None |
| Insertion of needle into vein for collection of blood sample | 18 | $57 | $3 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $34 | None |
| Unclassified drugs | 12 | $10 | None |
2019: 52 services
| Injection, pembrolizumab, 1 mg | 17 | $344,372 | None |
| Injection, denosumab, 1 mg | 27 | $167,440 | None |
| Injection, rituximab, 10 mg | 19 | $166,072 | None |
| Return visit (30+ min) | 469 | $118,550 | $86 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $118,170 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $91,874 | None |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $84,210 | None |
| Injection, pegfilgrastim, 6 mg | 12 | $67,887 | None |
| Administration of chemotherapy into vein, 1 hour or less | 150 | $60,356 | $128 |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $60,157 | None |
| Long return visit (40+ min) | 137 | $27,339 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 180 | $26,147 | $64 |
| Injection, tbo-filgrastim, 1 microgram | 19 | $15,844 | None |
| Injection, fosaprepitant, 1 mg | 26 | $13,015 | None |
| New patient visit (60+ min) | 74 | $12,340 | $167 |
| Cyclophosphamide, 100 mg | 11 | $8,058 | None |
| Injection of drug or substance under skin or into muscle | 92 | $7,837 | $15 |
| Drawing of blood for a medical problem | 33 | $6,192 | $86 |
| Injection, iron dextran, 50 mg | 24 | $6,084 | None |
| Administration of chemotherapy into vein, each additional hour | 65 | $5,895 | $28 |
| Injection of additional new drug or substance into vein | 92 | $5,852 | $15 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $5,707 | $73 |
| Collection of blood sample from implanted device | 63 | $5,445 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 63 | $5,437 | $28 |
| Administration of prolonged chemotherapy into vein | 19 | $4,979 | $131 |
| New patient visit (45+ min) | 39 | $4,827 | $124 |
| Administration of additional new drug or substance into vein using push technique | 32 | $4,525 | $54 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $4,450 | $63 |
| Injection, zoledronic acid, 1 mg | 89 | $3,445 | None |
| Infusion into a vein for hydration, 31-60 minutes | 37 | $3,164 | $34 |
| Short return visit (20+ min) | 39 | $2,676 | $54 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 24 | $2,559 | $20 |
| Instillation of anti-cancer drug into bladder | 14 | $2,501 | $74 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 78 | $1,797 | $8 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 66 | $1,683 | $21 |
| Injection, leucovorin calcium, per 50 mg | 19 | $1,460 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $1,409 | None |
| Irrigation of implanted venous access drug delivery device | 23 | $1,220 | $24 |
| Injection, oxaliplatin, 0.5 mg | 14 | $1,004 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $902 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 17 | $832 | $19 |
| Injection of drug or substance into vein | 23 | $824 | $34 |
| Injection, paclitaxel, 1 mg | 11 | $648 | None |
| Injection, doxorubicin hydrochloride, 10 mg | 13 | $628 | None |
| Injection, fluorouracil, 500 mg | 20 | $559 | None |
| Injection, carboplatin, 50 mg | 12 | $546 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 64 | $228 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 68 | $228 | None |
| Infusion, normal saline solution , 1000 cc | 39 | $200 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 13 | $167 | None |
| Insertion of needle into vein for collection of blood sample | 23 | $91 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $74 | None |
2018: 52 services
| Injection, nivolumab, 1 mg | 16 | $267,508 | None |
| Injection, rituximab, 100 mg | 23 | $238,417 | None |
| Injection, denosumab, 1 mg | 16 | $111,860 | None |
| Return visit (30+ min) | 461 | $111,274 | $85 |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $111,084 | None |
| Injection, pembrolizumab, 1 mg | 15 | $103,500 | None |
| Injection, pegfilgrastim, 6 mg | 13 | $91,709 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $89,231 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 18 | $69,959 | None |
| Administration of chemotherapy into vein, 1 hour or less | 153 | $58,641 | $126 |
| Long return visit (40+ min) | 133 | $25,064 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 159 | $22,480 | $64 |
| Injection, tbo-filgrastim, 1 microgram | 19 | $19,728 | None |
| New patient visit (60+ min) | 107 | $17,893 | $167 |
| Administration of prolonged chemotherapy into vein | 16 | $7,967 | $124 |
| Injection, fosaprepitant, 1 mg | 15 | $7,900 | None |
| Injection of drug or substance under skin or into muscle | 73 | $7,372 | $18 |
| Injection of additional new drug or substance into vein | 108 | $7,032 | $16 |
| Administration of chemotherapy into vein, each additional hour | 65 | $6,044 | $27 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 137 | $5,433 | $9 |
| New patient visit (45+ min) | 40 | $4,743 | $119 |
| Injection, zoledronic acid, 1 mg | 87 | $4,364 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $4,265 | $71 |
| Administration of additional new drug or substance into vein using push technique | 25 | $4,261 | $52 |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $3,986 | $60 |
| Drawing of blood for a medical problem | 21 | $3,494 | $85 |
| Infusion into a vein for hydration, 31-60 minutes | 31 | $3,273 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 26 | $3,267 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 43 | $2,974 | $28 |
| Short return visit (20+ min) | 39 | $2,565 | $56 |
| Injection, iron dextran, 50 mg | 12 | $2,514 | None |
| Injection, leucovorin calcium, per 50 mg | 16 | $2,085 | None |
| Injection of drug or substance into vein | 36 | $1,988 | $41 |
| Injection, oxaliplatin, 0.5 mg | 11 | $1,878 | None |
| Injection, iron sucrose, 1 mg | 19 | $1,807 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 16 | $1,603 | None |
| Collection of blood sample from implanted device | 36 | $1,575 | $22 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,349 | $112 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 47 | $1,090 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 15 | $982 | $18 |
| Irrigation of implanted venous access drug delivery device | 21 | $967 | $25 |
| Injection, fluorouracil, 500 mg | 16 | $836 | None |
| Injection, paclitaxel, 1 mg | 15 | $666 | None |
| Infusion into a vein for hydration, each additional hour | 19 | $637 | $12 |
| Insertion of needle into vein for collection of blood sample | 88 | $538 | $3 |
| Injection, carboplatin, 50 mg | 19 | $528 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 78 | $211 | None |
| Infusion, normal saline solution, 250 cc | 41 | $180 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 59 | $154 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 15 | $145 | None |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 12 | $131 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 50 | $58 | None |
2017: 40 services
| Injection, nivolumab, 1 mg | 12 | $307,513 | None |
| Injection, rituximab, 100 mg | 21 | $204,179 | None |
| Injection, pegfilgrastim, 6 mg | 21 | $152,753 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 17 | $144,043 | None |
| Return visit (30+ min) | 404 | $98,622 | $83 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $86,109 | None |
| Injection, denosumab, 1 mg | 19 | $68,324 | None |
| Administration of chemotherapy into vein, 1 hour or less | 140 | $59,237 | $117 |
| Injection, tbo-filgrastim, 1 microgram | 26 | $29,119 | None |
| Long return visit (40+ min) | 128 | $21,660 | $115 |
| New patient visit (60+ min) | 128 | $20,970 | $164 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 144 | $19,728 | $58 |
| Injection of drug or substance under skin or into muscle | 87 | $9,710 | $22 |
| Injection of additional new drug or substance into vein | 104 | $9,557 | $19 |
| Injection, fosaprepitant, 1 mg | 12 | $8,404 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 39 | $7,122 | $56 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $7,105 | $64 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 132 | $6,145 | $10 |
| Injection, zoledronic acid, 1 mg | 85 | $5,353 | None |
| Administration of chemotherapy into vein, each additional hour | 62 | $4,995 | $24 |
| Short return visit (20+ min) | 61 | $4,946 | $51 |
| Injection, iron dextran, 50 mg | 21 | $4,545 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $4,471 | $26 |
| Infusion into a vein for hydration, 31-60 minutes | 33 | $4,130 | $50 |
| Administration of additional new drug or substance into vein using push technique | 23 | $3,754 | $54 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 16 | $3,717 | None |
| Drawing of blood for a medical problem | 22 | $3,132 | $87 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 29 | $3,062 | $16 |
| Injection of drug or substance into vein | 35 | $2,597 | $46 |
| New patient visit (45+ min) | 19 | $2,029 | $107 |
| Injection, carboplatin, 50 mg | 17 | $867 | None |
| Injection, paclitaxel, 1 mg | 12 | $691 | None |
| Insertion of needle into vein for collection of blood sample | 82 | $556 | $3 |
| Infusion into a vein for hydration, each additional hour | 24 | $533 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 73 | $296 | None |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 15 | $215 | None |
| Infusion, normal saline solution, 250 cc | 51 | $203 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 56 | $163 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 11 | $155 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 46 | $60 | None |
2016: 37 services
| Injection, rituximab, 100 mg | 25 | $321,019 | None |
| Injection, nivolumab, 1 mg | 16 | $255,897 | None |
| Injection, pegfilgrastim, 6 mg | 23 | $172,638 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 14 | $108,244 | None |
| Return visit (30+ min) | 359 | $92,234 | $81 |
| Administration of chemotherapy into vein, 1 hour or less | 124 | $59,676 | $108 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 21 | $48,392 | None |
| Injection, tbo-filgrastim, 1 microgram | 28 | $27,622 | None |
| Long return visit (40+ min) | 108 | $19,609 | $115 |
| New patient visit (60+ min) | 98 | $16,122 | $165 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 104 | $14,199 | $58 |
| Injection of additional new drug or substance into vein | 106 | $12,275 | $19 |
| Administration of chemotherapy into vein, each additional hour | 47 | $7,825 | $24 |
| Injection, fosaprepitant, 1 mg | 12 | $7,690 | None |
| Injection of drug or substance under skin or into muscle | 76 | $7,377 | $21 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $7,362 | $53 |
| Injection, zoledronic acid, 1 mg | 76 | $6,978 | None |
| Short return visit (20+ min) | 78 | $6,637 | $53 |
| Infusion into a vein for hydration, 31-60 minutes | 33 | $5,305 | $47 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 127 | $4,169 | $10 |
| New patient visit (45+ min) | 27 | $3,215 | $119 |
| Injection of drug or substance into vein | 43 | $3,121 | $47 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 41 | $2,996 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $2,835 | $15 |
| Injection, iron dextran, 50 mg | 13 | $2,455 | None |
| Administration of chemotherapy into vein using push technique | 14 | $2,217 | $85 |
| Administration of additional new drug or substance into vein using push technique | 13 | $2,149 | $52 |
| Drawing of blood for a medical problem | 12 | $1,877 | $82 |
| Injection, paclitaxel, 1 mg | 24 | $1,725 | None |
| Injection, carboplatin, 50 mg | 24 | $1,478 | None |
| Infusion into a vein for hydration, each additional hour | 34 | $961 | $13 |
| Insertion of needle into vein for collection of blood sample | 88 | $570 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 78 | $351 | None |
| Infusion, normal saline solution, 250 cc | 54 | $238 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 61 | $197 | None |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 11 | $98 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 54 | $86 | None |
2015: 41 services
| Injection, rituximab, 100 mg | 21 | $263,339 | None |
| Injection, pegfilgrastim, 6 mg | 22 | $144,436 | None |
| Return visit (30+ min) | 306 | $99,559 | $87 |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $65,976 | None |
| Administration of chemotherapy into vein, 1 hour or less | 111 | $54,710 | $113 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $32,763 | None |
| Injection, tbo-filgrastim, 5 micrograms | 23 | $23,076 | None |
| Injection, zoledronic acid, 1 mg | 90 | $15,751 | None |
| New patient visit (60+ min) | 84 | $14,670 | $175 |
| Long return visit (40+ min) | 75 | $14,550 | $120 |
| Injection of additional new drug or substance into vein | 96 | $13,883 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 100 | $12,872 | $62 |
| Short return visit (20+ min) | 99 | $8,132 | $51 |
| Administration of prolonged chemotherapy into vein | 12 | $7,347 | $117 |
| Injection of drug or substance under skin or into muscle | 75 | $6,804 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 38 | $6,698 | $55 |
| Infusion into a vein for hydration, 31-60 minutes | 31 | $6,684 | $50 |
| Administration of chemotherapy into vein, each additional hour | 51 | $6,468 | $25 |
| Injection of drug or substance into vein | 59 | $4,799 | $50 |
| Administration of additional new drug or substance into vein using push technique | 20 | $4,377 | $55 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 108 | $3,547 | $10 |
| Injection, iron dextran, 50 mg | 21 | $3,037 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 50 | $2,989 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $2,962 | $16 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $2,857 | None |
| New patient visit (45+ min) | 20 | $2,599 | $130 |
| Injection, leucovorin calcium, per 50 mg | 12 | $2,546 | None |
| Drawing of blood for a medical problem | 14 | $2,146 | $83 |
| Injection, paclitaxel, 1 mg | 20 | $2,115 | None |
| Biopsy of bone marrow | 12 | $1,781 | $148 |
| Infusion into a vein for hydration, each additional hour | 33 | $1,169 | $13 |
| Injection, carboplatin, 50 mg | 16 | $1,120 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $1,067 | $18 |
| Injection, fluorouracil, 500 mg | 14 | $1,040 | None |
| Insertion of needle into vein for collection of blood sample | 105 | $779 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 72 | $370 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 60 | $209 | None |
| Infusion, normal saline solution, 250 cc | 46 | $190 | None |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 15 | $163 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 49 | $88 | None |
| Unclassified drugs | 12 | $19 | None |
2014: 41 services
| Injection, rituximab, 100 mg | 11 | $136,879 | None |
| Injection, pegfilgrastim, 6 mg | 21 | $96,813 | None |
| Return visit (30+ min) | 276 | $79,344 | $81 |
| Injection, zoledronic acid, 1 mg | 90 | $38,945 | None |
| Administration of chemotherapy into vein, 1 hour or less | 89 | $35,261 | $94 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 20 | $28,450 | None |
| Short return visit (20+ min) | 153 | $20,225 | $53 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 101 | $12,302 | $57 |
| New patient visit (60+ min) | 69 | $11,313 | $164 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 18 | $10,909 | None |
| Injection of additional new drug or substance into vein | 83 | $10,814 | $19 |
| Long return visit (40+ min) | 69 | $9,816 | $109 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $6,323 | $58 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $5,400 | $52 |
| Injection of drug or substance under skin or into muscle | 77 | $5,301 | $20 |
| Administration of additional new drug or substance into vein using push technique | 21 | $4,363 | $51 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 100 | $3,796 | $10 |
| Injection of drug or substance into vein | 47 | $3,507 | $47 |
| Administration of chemotherapy into vein, each additional hour | 33 | $3,425 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $3,097 | $15 |
| Injection, iron dextran, 50 mg | 15 | $3,094 | None |
| New patient visit (45+ min) | 23 | $2,959 | $129 |
| Infusion into a vein for hydration, 31-60 minutes | 30 | $2,816 | $48 |
| Drawing of blood for a medical problem | 19 | $2,401 | $77 |
| Injection, paclitaxel, 30 mg | 21 | $2,349 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $2,111 | $25 |
| Biopsy of bone marrow | 14 | $1,921 | $137 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,374 | None |
| Injection, carboplatin, 50 mg | 17 | $1,206 | None |
| Insertion of needle into vein for collection of blood sample | 135 | $1,025 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $779 | $17 |
| Injection, fluorouracil, 500 mg | 11 | $680 | None |
| Irrigation of implanted venous access drug delivery device | 20 | $437 | $17 |
| Infusion into a vein for hydration, each additional hour | 18 | $375 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 66 | $325 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $249 | $14 |
| Injection, ondansetron hydrochloride, per 1 mg | 45 | $158 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 12 | $123 | $10 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $80 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $77 | None |
| Infusion, normal saline solution, 250 cc | 39 | $63 | None |
2013: 37 services
| Injection, rituximab, 100 mg | 19 | $229,896 | None |
| Injection, pegfilgrastim, 6 mg | 27 | $172,908 | None |
| Return visit (30+ min) | 247 | $74,684 | $82 |
| Zoldedronic acid 1mg | 58 | $52,278 | $134 |
| Administration of chemotherapy into vein, 1 hour or less | 71 | $32,444 | $96 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $27,715 | None |
| Injection, zoledronic acid (zometa), 1 mg | 12 | $21,508 | None |
| Injection, filgrastim (g-csf), 480 mcg | 18 | $20,401 | None |
| Injection, zoledronic acid (reclast), 1 mg | 24 | $20,277 | None |
| Short return visit (20+ min) | 144 | $18,600 | $55 |
| Long return visit (40+ min) | 77 | $11,777 | $112 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 107 | $9,828 | $58 |
| Injection, palonosetron hcl, 25 mcg | 13 | $8,641 | None |
| New patient visit (60+ min) | 43 | $7,068 | $164 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $6,955 | $60 |
| Injection of additional new drug or substance into vein | 55 | $6,810 | $19 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $5,488 | $64 |
| Injection of drug or substance under skin or into muscle | 68 | $5,119 | $21 |
| Administration of chemotherapy into vein, each additional hour | 35 | $4,939 | $26 |
| Infusion into a vein for hydration, 31-60 minutes | 31 | $3,892 | $48 |
| Irrigation of implanted venous access drug delivery device | 43 | $3,506 | $21 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 89 | $3,336 | $11 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 32 | $2,736 | $27 |
| New patient visit (45+ min) | 18 | $2,394 | $133 |
| Drawing of blood for a medical problem | 14 | $2,123 | $79 |
| Biopsy of bone marrow | 15 | $2,098 | $140 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $1,814 | $17 |
| Insertion of needle into vein for collection of blood sample | 117 | $1,028 | $3 |
| Injection, paclitaxel, 30 mg | 12 | $868 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $474 | $16 |
| Infusion into a vein for hydration, each additional hour | 16 | $422 | $13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 44 | $189 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $182 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 15 | $151 | $10 |
| Infusion, normal saline solution , 1000 cc | 30 | $59 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 27 | $49 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 29 | $20 | None |
Medicaid work
$763 in 2024
Medicaid paid $763 for 28 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 28 | $763 |
| 2024 | 28 | 1 | 13 | $763 |
| 2023 | 178 | 4 | 21 | $9,090 |
| 2022 | 125 | 2 | 17 | $7,746 |
| 2021 | 260 | 2 | 23 | $25,062 |
| 2020 | 245 | 2 | 23 | $16,562 |
| 2019 | 315 | 3 | 25 | $18,850 |
| 2018 | 287 | 3 | 30 | $20,689 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 69 | $3,943 |
| Return visit (30+ min) | 79 | $3,847 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 13 | $938 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 17 | $362 |
2022
| Return visit (30+ min) | 88 | $5,338 |
| Long return visit (40+ min) | 37 | $2,408 |
2021
| Return visit (30+ min) | 178 | $17,496 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 82 | $7,566 |
2020
| Return visit (30+ min) | 193 | $13,228 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 52 | $3,334 |
2019
| Return visit (30+ min) | 278 | $17,219 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 21 | $1,316 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 16 | $314 |
2018
| Return visit (30+ min) | 238 | $17,416 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 34 | $3,220 |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $53 |
Drugs they prescribed that Part D paid
$4,056,309
Pharmacies billed $4,056,309 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (22 of 1,107) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
868 generic and 239 brand-name prescriptions · $4,056,309 in drug cost · 34 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 50 | $609,238 | $12,185 |
| Lenalidomide | 49 | $594,211 | $12,127 |
| Ibrance | 26 | $397,927 | $15,305 |
| Tagrisso | 23 | $362,214 | $15,748 |
| Cabometyx | 12 | $312,513 | $26,043 |
See all 24 drugs
| Brukinsa | 50 | $609,238 | $12,185 |
| Lenalidomide | 49 | $594,211 | $12,127 |
| Ibrance | 26 | $397,927 | $15,305 |
| Tagrisso | 23 | $362,214 | $15,748 |
| Cabometyx | 12 | $312,513 | $26,043 |
| Stivarga | 14 | $245,534 | $17,538 |
| Imbruvica | 15 | $241,670 | $16,111 |
| Xtandi | 13 | $187,981 | $14,460 |
| Abiraterone Acetate | 48 | $44,294 | $923 |
| Eliquis | 19 | $22,474 | $1,183 |
| Exemestane | 27 | $6,895 | $255 |
| Letrozole | 39 | $2,087 | $54 |
| Acyclovir | 96 | $1,955 | $20 |
| Anastrozole | 80 | $1,915 | $24 |
| Hydroxyurea | 62 | $1,790 | $29 |
| Tamoxifen Citrate | 37 | $933 | $25 |
| Dexamethasone | 39 | $769 | $20 |
| Prochlorperazine Maleate | 46 | $516 | $11 |
| Prednisone | 102 | $491 | $5 |
| Valacyclovir | 13 | $431 | $33 |
| Ondansetron | 41 | $300 | $7 |
| Lidocaine-Prilocaine | 22 | $263 | $12 |
| Sulfamethoxazole-Trimethoprim | 23 | $154 | $7 |
| Allopurinol | 12 | $84 | $7 |
Year by year
| 2024 | 1,107 | 192 | 2% (22) | 22% | $4,056,309 |
| 2023 | 913 | 183 | 2% (18) | 18% | $2,742,052 |
| 2022 | 733 | 148 | 4% (28) | 22% | $1,953,897 |
| 2021 | 772 | 146 | 4% (32) | 16% | $1,427,180 |
| 2020 | 865 | 170 | 5% (39) | 22% | $2,186,403 |
| 2019 | 895 | 185 | 3% (23) | 31% | $3,108,234 |
| 2018 | 918 | 176 | 3% (31) | 33% | $3,069,245 |
| 2017 | 801 | 162 | 3% (23) | 29% | $2,211,595 |
| 2016 | 506 | 131 | 7% (36) | 31% | $1,534,529 |
| 2015 | 373 | 101 | 14% (52) | 28% | $802,053 |
| 2014 | 473 | 93 | 11% (52) | 25% | $811,228 |
| 2013 | 415 | 95 | 12% (49) | 29% | $810,632 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Revlimid | 33 | $593,692 | $17,991 |
| Brukinsa | 26 | $373,094 | $14,350 |
| Lenalidomide | 23 | $331,858 | $14,429 |
| Jakafi | 13 | $241,947 | $18,611 |
| Imbruvica | 12 | $190,816 | $15,901 |
| Ibrance | 11 | $178,370 | $16,215 |
| Votrient | 11 | $150,127 | $13,648 |
| Abiraterone Acetate | 32 | $52,689 | $1,647 |
| Eliquis | 13 | $15,137 | $1,164 |
| Exemestane | 19 | $5,291 | $278 |
| Letrozole | 57 | $3,891 | $68 |
| Anastrozole | 80 | $1,959 | $24 |
| Hydroxyurea | 37 | $1,354 | $37 |
| Acyclovir | 74 | $1,347 | $18 |
| Tamoxifen Citrate | 20 | $1,017 | $51 |
| Prochlorperazine Maleate | 60 | $748 | $12 |
| Dexamethasone | 38 | $654 | $17 |
| Prednisone | 70 | $551 | $8 |
| Ondansetron | 37 | $424 | $11 |
| Valacyclovir | 16 | $402 | $25 |
| Lidocaine-Prilocaine | 17 | $260 | $15 |
| Hydrocodone-Acetaminophen | 14 | $203 | $14 |
| Sulfamethoxazole-Trimethoprim | 23 | $189 | $8 |
| Omeprazole | 12 | $185 | $15 |
2022: 18 drugs
| Revlimid | 29 | $474,722 | $16,370 |
| Imbruvica | 30 | $447,576 | $14,919 |
| Xtandi | 22 | $294,680 | $13,395 |
| Votrient | 12 | $147,891 | $12,324 |
| Imatinib Mesylate | 13 | $64,738 | $4,980 |
| Xarelto | 18 | $15,512 | $862 |
| Letrozole | 50 | $2,288 | $46 |
| Anastrozole | 67 | $1,799 | $27 |
| Hydroxyurea | 26 | $1,345 | $52 |
| Acyclovir | 49 | $945 | $19 |
| Tamoxifen Citrate | 15 | $904 | $60 |
| Dexamethasone | 41 | $759 | $19 |
| Prochlorperazine Maleate | 41 | $635 | $15 |
| Ondansetron | 24 | $502 | $21 |
| Hydrocodone-Acetaminophen | 21 | $350 | $17 |
| Prednisone | 29 | $326 | $11 |
| Omeprazole | 18 | $270 | $15 |
| Sulfamethoxazole-Trimethoprim | 11 | $18 | $2 |
2021: 19 drugs
| Revlimid | 23 | $396,368 | $17,233 |
| Imbruvica | 20 | $281,915 | $14,096 |
| Ibrance | 12 | $159,333 | $13,278 |
| Votrient | 12 | $139,572 | $11,631 |
| Abiraterone Acetate | 19 | $12,629 | $665 |
| Exemestane | 21 | $5,858 | $279 |
| Anastrozole | 77 | $1,924 | $25 |
| Letrozole | 43 | $1,700 | $40 |
| Dexamethasone | 49 | $1,299 | $27 |
| Tamoxifen Citrate | 18 | $1,008 | $56 |
| Prochlorperazine Maleate | 70 | $968 | $14 |
| Hydroxyurea | 17 | $949 | $56 |
| Acyclovir | 37 | $925 | $25 |
| Ondansetron | 46 | $735 | $16 |
| Prednisone | 53 | $549 | $10 |
| Lidocaine-Prilocaine | 18 | $448 | $25 |
| Hydrocodone-Acetaminophen | 23 | $323 | $14 |
| Lorazepam | 18 | $93 | $5 |
| Sulfamethoxazole-Trimethoprim | 14 | $92 | $7 |
2020: 18 drugs
| Revlimid | 42 | $715,636 | $17,039 |
| Imbruvica | 48 | $646,695 | $13,473 |
| Abiraterone Acetate | 28 | $38,406 | $1,372 |
| Xarelto | 13 | $15,493 | $1,192 |
| Exemestane | 24 | $14,894 | $621 |
| Eliquis | 11 | $5,410 | $492 |
| Anastrozole | 94 | $3,009 | $32 |
| Tamoxifen Citrate | 25 | $1,841 | $74 |
| Dexamethasone | 65 | $1,322 | $20 |
| Hydroxyurea | 24 | $1,002 | $42 |
| Prochlorperazine Maleate | 75 | $910 | $12 |
| Ondansetron | 54 | $680 | $13 |
| Prednisone | 66 | $571 | $9 |
| Acyclovir | 47 | $525 | $11 |
| Lidocaine-Prilocaine | 27 | $520 | $19 |
| Hydrocodone-Acetaminophen | 25 | $281 | $11 |
| Omeprazole | 11 | $95 | $9 |
| Sulfamethoxazole-Trimethoprim | 16 | $88 | $6 |
2019: 25 drugs
| Revlimid | 54 | $878,309 | $16,265 |
| Imbruvica | 43 | $529,476 | $12,313 |
| Tagrisso | 30 | $471,312 | $15,710 |
| Pomalyst | 21 | $371,699 | $17,700 |
| Ibrance | 15 | $188,770 | $12,585 |
| Zytiga | 22 | $187,210 | $8,510 |
| Inlyta | 12 | $129,106 | $10,759 |
| Abiraterone Acetate | 16 | $88,103 | $5,506 |
| Xarelto | 22 | $16,397 | $745 |
| Exemestane | 29 | $15,755 | $543 |
| Eliquis | 13 | $6,098 | $469 |
| Anastrozole | 136 | $4,412 | $32 |
| Tamoxifen Citrate | 53 | $3,207 | $61 |
| Raloxifene | 12 | $1,138 | $95 |
| Letrozole | 21 | $984 | $47 |
| Dexamethasone | 42 | $946 | $23 |
| Hydroxyurea | 23 | $889 | $39 |
| Prochlorperazine Maleate | 59 | $561 | $10 |
| Ondansetron | 48 | $496 | $10 |
| Bicalutamide | 14 | $355 | $25 |
| Acyclovir | 11 | $338 | $31 |
| Lidocaine-Prilocaine | 16 | $293 | $18 |
| Potassium Chloride | 11 | $285 | $26 |
| Prednisone | 40 | $246 | $6 |
| Hydrocodone-Acetaminophen | 12 | $207 | $17 |
2018: 25 drugs
| Revlimid | 52 | $854,029 | $16,424 |
| Ibrance | 33 | $395,159 | $11,975 |
| Imbruvica | 32 | $373,946 | $11,686 |
| Zytiga | 37 | $354,144 | $9,571 |
| Pomalyst | 18 | $308,516 | $17,140 |
| Tagrisso | 12 | $181,065 | $15,089 |
| Inlyta | 13 | $177,661 | $13,666 |
| Xtandi | 18 | $154,984 | $8,610 |
| Xarelto | 42 | $23,395 | $557 |
| Exemestane | 40 | $17,914 | $448 |
| Anastrozole | 156 | $3,677 | $24 |
| Tamoxifen Citrate | 72 | $3,546 | $49 |
| Enoxaparin | 12 | $2,930 | $244 |
| Hydroxyurea | 27 | $1,392 | $52 |
| Acyclovir | 20 | $482 | $24 |
| Dexamethasone | 26 | $444 | $17 |
| Lidocaine-Prilocaine | 14 | $389 | $28 |
| Prednisone | 55 | $384 | $7 |
| Hydrocodone-Acetaminophen | 20 | $338 | $17 |
| Ondansetron | 24 | $276 | $11 |
| Bicalutamide | 11 | $227 | $21 |
| Prochlorperazine Maleate | 32 | $169 | $5 |
| Letrozole | 16 | $105 | $7 |
| Lorazepam | 15 | $76 | $5 |
| Gabapentin | 13 | $67 | $5 |
2017: 18 drugs
| Revlimid | 48 | $740,334 | $15,424 |
| Imbruvica | 42 | $471,147 | $11,218 |
| Zytiga | 27 | $226,093 | $8,374 |
| Pomalyst | 18 | $222,667 | $12,370 |
| Ibrance | 16 | $189,045 | $11,815 |
| Inlyta | 13 | $179,490 | $13,807 |
| Xarelto | 30 | $12,357 | $412 |
| Exemestane | 18 | $10,729 | $596 |
| Anastrozole | 141 | $3,679 | $26 |
| Tamoxifen Citrate | 67 | $3,485 | $52 |
| Hydroxyurea | 34 | $1,441 | $42 |
| Acyclovir | 34 | $605 | $18 |
| Prednisone | 62 | $585 | $9 |
| Hydrocodone-Acetaminophen | 13 | $267 | $21 |
| Ondansetron | 20 | $257 | $13 |
| Dexamethasone | 24 | $216 | $9 |
| Prochlorperazine Maleate | 29 | $203 | $7 |
| Azithromycin | 11 | $103 | $9 |
2016: 9 drugs
| Revlimid | 66 | $857,287 | $12,989 |
| Imbruvica | 31 | $316,711 | $10,216 |
| Votrient | 17 | $155,140 | $9,126 |
| Exemestane | 11 | $2,872 | $261 |
| Tamoxifen Citrate | 46 | $1,522 | $33 |
| Anastrozole | 62 | $1,331 | $21 |
| Hydroxyurea | 43 | $1,048 | $24 |
| Hydrocodone-Acetaminophen | 20 | $596 | $30 |
| Prednisone | 34 | $364 | $11 |
2015: 9 drugs
| Revlimid | 36 | $424,059 | $11,779 |
| Votrient | 15 | $130,604 | $8,707 |
| Exemestane | 13 | $4,966 | $382 |
| Anastrozole | 51 | $918 | $18 |
| Hydrocodone-Acetaminophen | 25 | $862 | $34 |
| Hydroxyurea | 19 | $665 | $35 |
| Tamoxifen Citrate | 22 | $594 | $27 |
| Ondansetron | 12 | $123 | $10 |
| Lorazepam | 15 | $73 | $5 |
2014: 16 drugs
| Revlimid | 42 | $419,147 | $9,980 |
| Xtandi | 12 | $98,582 | $8,215 |
| Pomalyst | 11 | $82,854 | $7,532 |
| Inlyta | 11 | $74,464 | $6,769 |
| Exemestane | 15 | $5,187 | $346 |
| Tamoxifen Citrate | 33 | $839 | $25 |
| Anastrozole | 36 | $831 | $23 |
| Hydrocodone-Acetaminophen | 36 | $808 | $22 |
| Hydroxyurea | 20 | $464 | $23 |
| Ondansetron | 19 | $275 | $14 |
| Dexamethasone | 28 | $259 | $9 |
| Prednisone | 15 | $167 | $11 |
| Acyclovir | 13 | $164 | $13 |
| Prochlorperazine Maleate | 21 | $156 | $7 |
| Lorazepam | 21 | $109 | $5 |
| Sulfamethoxazole-Trimethoprim | 13 | $66 | $5 |
2013: 8 drugs
| Revlimid | 51 | $408,014 | $8,000 |
| Pomalyst | 15 | $124,947 | $8,330 |
| Anastrozole | 56 | $2,292 | $41 |
| Hydrocodone-Acetaminophen | 33 | $791 | $24 |
| Hydroxyurea | 18 | $581 | $32 |
| Tamoxifen Citrate | 20 | $467 | $23 |
| Lidocaine Hcl Viscous | 15 | $148 | $10 |
| Prednisone | 11 | $60 | $5 |
Money from drug and device companies
$339 in 2025
| 2025 | 11 | 13 | None | $339 |
| 2024 | 15 | 20 | None | $498 |
| 2023 | 2 | 2 | None | $45 |
| 2022 | 1 | 3 | None | $38 |
| 2021 | 1 | 2 | None | $24 |
| 2020 | 1 | 1 | None | $13 |
| 2019 | 1 | 1 | None | $17 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Leqvio | $56 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $38 | 2 payments
|
| Geron | Rytelo | $34 | 1 payment
|
| Pfizer | Bosulif | $33 | 1 payment
|
| PharmaEssentia USA | Besremi | $31 | 1 payment
|
| Janssen Biotech | Rybrevant | $31 | 1 payment
|
See all 13 published payments
| GlaxoSmithKline | Meals · 2025-12-04 | Blenrep | $25 |
| Janssen Biotech | Meals · 2025-10-13 | Rybrevant | $31 |
| Novartis Pharmaceuticals | Meals · 2025-09-10 | Ilaris | $23 |
| Novartis Pharmaceuticals | Meals · 2025-08-14 | Leqvio | $32 |
| Merck Sharp & Dohme | Meals · 2025-07-22 | Keytruda | $28 |
| Geron | Meals · 2025-06-17 | Rytelo | $34 |
| Incyte | Meals · 2025-05-22 | Jakafi | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-15 | Opdivo | $20 |
| Indivior | Meals · 2025-03-25 | Sublocade | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-04 | Opdivo | $18 |
| Pfizer | Meals · 2025-01-23 | Bosulif | $33 |
| SpringWorks Therapeutics | Meals · 2025-01-09 | None | $24 |
| PharmaEssentia USA | Meals · 2025-01-07 | Besremi | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $498
| Celgene | Reblozyl | $67 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $47 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $42 | 2 payments
|
| Array Biopharma | Braftovi | $42 | 2 payments
|
| Amgen | Evenity | $40 | 1 payment
|
| GlaxoSmithKline | Jemperli | $33 | 1 payment
|
| Eisai | Lenvima | $32 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $32 | 1 payment
|
| Puma Biotechnology | None | $29 | 1 payment
|
| Astellas Pharma US | Padcev | $28 | 1 payment
|
| Pfizer | Inlyta | $24 | 1 payment
|
| Daiichi Sankyo | Enhertu | $24 | 1 payment
|
| Incyte | Jakafi | $22 | 1 payment
|
| Genmab U.S. | Epkinly | $22 | 1 payment
|
| Janssen Biotech | Erleada | $15 | 1 payment
|
2023: $45
| Janssen Biotech | None | $26 | 1 payment
|
| EMD Serono | Bavencio | $18 | 1 payment
|
2022: $38
| Acrotech Biopharma | Beleodaq | $38 | 3 payments
|
2021: $24
| Acrotech Biopharma | Beleodaq | $24 | 2 payments
|
2020: $13
| Merck Sharp & Dohme | Lenvima | $13 | 1 payment
|
2019: $17
| Stemline Therapeutics | Elzonris | $17 | 1 payment
|
Professional record
- NPI
- 1063537934
- Licence
- CA 20A10095
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2025 Soquel Ave, Santa Cruz, CA, 95062
- NPI first listed
- 2007-03-20
- NPI last updated
- 2011-11-04
This is when the NPI record was last certified, not a medical board exam.